<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728725</url>
  </required_header>
  <id_info>
    <org_study_id>7162-02/2</org_study_id>
    <nct_id>NCT03728725</nct_id>
  </id_info>
  <brief_title>Xpert MTB/XDR Clinical Evaluation Trial</brief_title>
  <official_title>Multicentre Clinical Trial to Assess the Performance of the Xpert MTB/XDR Assay for INH- and Second-line Resistance Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cepheid</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PD Hinduja Hospital and Medical Research Centre, Mumbai, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phthisiopneumology Institute, Chisinau, Moldova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Tuberculosis and Respiratory Disease, New Delhi, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FIND and partners intend to address the need for a multi- and extensively drug-resistant
      tuberculosis (M/XDR-TB) diagnostic solution for patients in settings with a high burden of
      drug-resistant tuberculosis (DR-TB) though the development, evaluation and introduction of an
      Xpert MTB/XDR assay
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for INH and ETH resistance detection</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity and specificity estimates for INH and ETH resistance detection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for fluoroquinolone resistance detection</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity and specificity estimates for fluoroquinolone resistance detection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for second-line injectable resistance detection</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity and specificity estimates for second-line injectable resistance detection</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>TB case detection Group</arm_group_label>
    <description>Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIF-resistance MTB Group</arm_group_label>
    <description>An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.
/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cepheid Gene Xpert MTB/XDR</intervention_name>
    <description>The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.</description>
    <arm_group_label>RIF-resistance MTB Group</arm_group_label>
    <arm_group_label>TB case detection Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum will be collected from consenting, enrolled adult participants. Sputum samples may
      voluntarily be stored for up to 20 years.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals who have one or more risk factors for DR-TB presenting to participating centres
        will be screened by Xpert MTB/RIF or Ultra. Those who test MTB-positive by Xpert MTB/RIF or
        Ultra at the study sites will be asked to participate. Individuals will be recruited at
        outpatient clinic settings and inpatient hospital settings. HIV-positive individuals and
        HIV-negative individuals will be included in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Age 18 years or above;

               -  Symptoms suggesting pulmonary TB, i.e. persistent cough (generally ≥3 weeks or as
                  per local definition of TB suspect), and at least one of the following:

                    -  Previously received &gt;1 month of treatment for a prior TB episode or

                    -  Failing TB treatment with positive sputum smear or culture after ≥3 months
                       of a standard TB treatment or

                    -  Had close contact with a known drug-resistant TB case or

                    -  Newly diagnosed with MDR-TB within the last 30 days or

                    -  Previously diagnosed with MDR-TB and failed TB treatment with positive
                       sputum smear or culture after ≥3 months of a standard MDR-TB treatment
                       regimen

        Patients meeting the above criteria will be screened by Xpert MTB/RIF or Xpert MTB/RIF
        Ultra. TB patients meeting the following criteria will be included in the study:

          -  A clear Mtb-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or
             Xpert MTB/RIF Ultra

          -  Provision of informed consent;

          -  Production of an adequate quantity (&gt;3mL) of sputum

        Exclusion Criteria:

          -  Participants will be excluded from the study if informed consent is not provided.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Penn-Nicholsson, PhD</last_name>
    <phone>+4122710 05 90</phone>
    <email>adam.penn-nicholson@finddx.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Pthisiopenumology</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriu Crudu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03728725/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03728725/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

